β-Glycosphingolipids as Immune Modulators

REFERENCES

• Adar T., Ben-Ami R., Elstein D., Zimran A., Berliner S., Yedgar S., Barshtein G. Aggregation of red blood cells in patients with Gaucher disease. Br. J. Haematol. 2006; 134: 432–437
   PubMed Web of Science ®Google Scholar
• Apostolou I., Takahama Y., Belmant C., Kawano T., Huerre M., Marchal G., Cui J., Taniguchi M., Nakauchi H., Fournie J. J., Kourilsky P., Gachelin G. Murine natural killer T(NKT)-cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. USA 1999; 96: 5141–5146
   PubMed Web of Science ®Google Scholar
• Arase H., Arase N., Nakagawa K., Good R. A., Onoe K. NK1.1+ CD4+CD8− thymocytes with specific lymphokine secretion. Eur. J. Immunol. 1993; 23: 307–310
   PubMed Web of Science ®Google Scholar
• Bendelac A., Lantz O., Quimby M. E., Yewdell J. W., Bennink J. R., Brutkiewicz R. R. CD1 recognition by mouse NK1+ T-lymphocytes. Science 1995; 268: 863–865
   PubMed Web of Science ®Google Scholar
• Bendelac A., Rivera M. N., Park S. H., Roark Mouse J. H. CD1-specific NK1 T-cells: Development, specificity, and function. Annu. Rev. Immunol. 1997; 15: 535–562
   PubMed Web of Science ®Google Scholar
• Bendelac A., Savage P. B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007; 25: 297–336
   PubMed Web of Science ®Google Scholar
• Berzins S. P., Smyth M. J., Godfrey D. I. Working with NKT cells - pitfalls and practicalities. Curr. Opin. Immunol. 2005; 17: 448–454
   PubMed Web of Science ®Google Scholar
• Bezbradica J. S., Stanic A. K., Matsuki N., Bour-Jordan H., Bluestone J. A., Thomas J. W., Unutmaz D., Van Kaer L., Joyce S. Distinct roles of dendritic cells and B-cells in Vα 14Jα 18 natural T-cell activation in vivo. J. Immunol. 2005; 174: 4696–4705
   PubMed Web of Science ®Google Scholar
• Bittman R. The 2003 ASBMB-Avanti Award in Lipids Address: Applications of novel synthetic lipids to biological problems. Chem. Phys. Lipids 2004; 129: 111–131
   PubMedGoogle Scholar
• Brigl M., Brenner M. B. CD1: Antigen presentation and T-cell function. Annu. Rev. Immunol. 2004; 22: 817–890
   PubMed Web of Science ®Google Scholar
• Brockman H. L., Momsen M. M., Brown R. E., He L., Chun J., Byun H. S., Bittman R. The 4,5-double bond of ceramide regulates its dipole potential, elastic properties, and packing behavior. Biophys. J. 2004; 87: 1722–1731
   PubMedGoogle Scholar
• Brossay L., Chioda M., Burdin N., Koezuka Y., Casorati G., Dellabona P., Kronenberg M. CD1d-mediated recognition of an α -galactosylceramide by natural killer T-cells is highly conserved through mammalian evolution. J. Exp. Med. 1998; 188: 1521–1528
   PubMed Web of Science ®Google Scholar
• Brossay L., Jullien D., Cardell S., Sydora B. C., Burdin N., Modlin R. L., Kronenberg M. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J. Immunol. 1997; 159: 1216–1224
   PubMed Web of Science ®Google Scholar
• Brutkiewicz R. R. CD1d ligands: The good, the bad, and the ugly. J. Immunol. 2006; 177: 769–775
   PubMed Web of Science ®Google Scholar
• Burdin N., Brossay L., Kronenberg M. Immunization with α -galactosylceramide polarizes CD1-reactive NK T-cells towards TH2 cytokine synthesis. Eur. J. Immunol. 1999; 29: 2014–2025, 1999
   PubMed Web of Science ®Google Scholar
• Carnaud C., Lee D., Donnars O., Park S. H., Beavis A., Koezuka Y., Bendelac A. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 1999; 163: 4647–4650
   PubMed Web of Science ®Google Scholar
• Chackerian A., Alt J., Perera V., Behar S. M. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 2002; 70: 6302–6309
   PubMed Web of Science ®Google Scholar
• Chang Y. J., Huang J. R., Tsai Y. C., Hung J. T., Wu D., Fujio M., Wong C. H., Yu A. L. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl. Acad. Sci. USA 2007; 104: 10299–10304
   PubMed Web of Science ®Google Scholar
• Crispe I. N. Hepatic T-cells and liver tolerance. Nat. Rev. Immunol. 2003; 3: 51–62
   PubMed Web of Science ®Google Scholar
• Crowe N. Y., Smyth M. J., Godfrey D. I. A critical role for natural killer T-cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 2002; 196: 119–127
   PubMed Web of Science ®Google Scholar
• Cui J., Watanabe N., Kawano T., Yamashita M., Kamata T., Shimizu C., Kimura M., Shimizu E., Koike J., Koseki H., Tanaka Y., Taniguchi M., Nakayama T. Inhibition of T-helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα 14 natural killer T-cells. J. Exp. Med. 1999; 190: 783–792
   PubMed Web of Science ®Google Scholar
• De Silva A. D., Park J. J., Matsuki N., Stanic A. K., Brutkiewicz R. R., Medof M. E., Joyce S. Lipid protein interactions: The assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 2002; 168: 723–733
   PubMed Web of Science ®Google Scholar
• Dellabona P., Padovan E., Casorati G., Brockhaus M., Lanzavecchia A. An invariant V α 24-Jα Q/Vβ 11 T-cell receptor is expressed in all individuals by clonally expanded CD4−CD8− T-cells. J. Exp. Med. 1994; 180: 1171–1176
   PubMed Web of Science ®Google Scholar
• Doherty D. G., Norris S., Madrigal-Estebas L., McEntee G., Traynor O., Hegarty J. E., O'Farrelly C. The human liver contains multiple populations of NK cells, T-cells, and CD3+CD56+ natural T-cells with distinct cytotoxic activities and TH1, TH2, and TH0 cytokine secretion patterns. J. Immunol. 1999; 163: 2314–2321
   PubMed Web of Science ®Google Scholar
• Eberl G., Brawand P., MacDonald H. R. Selective bystander proliferation of memory CD4+ and CD8+ T-cells upon NK T- or T-cell activation. J. Immunol. 2000; 165: 4305–4311
   PubMedGoogle Scholar
• Eberl G., MacDonald H. R. Rapid death and regeneration of NKT cells in anti-CD3ε - or IL-12-treated mice: A major role for bone marrow in NKT cell homeostasis. Immunity 1998; 9: 345–353
   PubMed Web of Science ®Google Scholar
• Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher's disease. Lancet 2001; 358: 324–327
   PubMed Web of Science ®Google Scholar
• Gansert J. L., Kiessler V., Engele M., Wittke F., Rollinghoff M., Krensky A. M., Porcelli S. A., Modlin R. L., Stenger S. Human NKT cells express granulysin and exhibit antimycobacterial activity. J. Immunol. 2003; 170: 3154–3161
   PubMed Web of Science ®Google Scholar
• Giabbai B., Sidobre S., Crispin M. D., Sanchez-Ruiz Y., Bachi A., Kronenberg M., Wilson I. A., Degano M. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: A molecular basis for NKT cell activation. J. Immunol. 2005; 175: 977–984
   PubMedGoogle Scholar
• Godfrey D. I., Hammond K. J., Poulton L. D., Smyth M. J., Baxter A. G. NKT cells: Facts, functions and fallacies. Immunol. Today 2000; 21: 573–583
   PubMedGoogle Scholar
• Godfrey D. I., Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 2004; 114: 1379–1388
   PubMed Web of Science ®Google Scholar
• Godfrey D. I., MacDonald H. R., Kronenberg M., Smyth M. J., Van Kaer L. NKT cells: What's in a name?. Nat. Rev. Immunol. 2004; 4: 231–237
   PubMed Web of Science ®Google Scholar
• Godfrey D. I., McConville M. J., Pellicci D. G. Chewing the fat on natural killer T-cell development. J. Exp. Med. 2006; 203: 2229–2232
   PubMedGoogle Scholar
• Goni F. M., Alonso A. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim. Biophys. Acta 2006; 1758: 1902–1921
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G., de Oliveira C., Tomaska M., Hong S., Bruna-Romero O., Nakayama T., Taniguchi M., Bendelac A., Van Kaer L., Koezuka Y., Tsuji M. α -galactosylceramide-activated Vα 14 natural killer T-cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 2000; 97: 8461–8466
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C. C., Wilson J. M., Schmieg J., Kronenberg M., Nakayama T., Taniguchi M., Koezuka Y., Tsuji M. Natural killer T-cell ligand α -galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 2002; 195: 617–624
   PubMed Web of Science ®Google Scholar
• Gumperz J. E., Brenner M. B. CD1-specific T-cells in microbial immunity. Curr. Opin. Immunol. 2001; 13: 471–478
   PubMedGoogle Scholar
• Hammond K. J., Poulton L. D., Palmisano L. J., Silveira P. A., Godfrey D. I., Baxter A. G. α β -T-cell receptor (TCR)+CD4−CD8− (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 1998; 187: 1047–1056, 1998
   PubMed Web of Science ®Google Scholar
• Hansen D. S., Schofield L. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int. J. Parasitol. 2004; 34: 15–25
   PubMed Web of Science ®Google Scholar
• Hauben E., Roncarolo M. G., Nevo U., Schwartz M. Beneficial autoimmunity in Type 1 diabetes mellitus. Trends Immunol. 2005; 26: 248–253
   PubMed Web of Science ®Google Scholar
• Hayakawa K., Lin B. T., Hardy R. R. Murine thymic CD4+ T-cell subsets: A subset (Thy0) that secretes diverse cytokines and over-expresses the Vβ 8 T-cell receptor gene family. J. Exp. Med. 1992; 176: 269–274
   PubMed Web of Science ®Google Scholar
• Hermans I. F., Silk J. D., Gileadi U., Salio M., Mathew B., Ritter G., Schmidt R., Harris A. L., Old L., Cerundolo V. NKT cells enhance CD4+ and CD8+ T-cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 2003; 171: 5140–5147
   PubMed Web of Science ®Google Scholar
• Hong S., Wilson M. T., Serizawa I., Wu L., Singh N., Naidenko O. V., Miura T., Haba T., Scherer D. C., Wei J., Kronenberg M., Koezuka Y., Van Kaer L. The natural killer T-cell ligand α -galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001; 7: 1052–1056
   PubMed Web of Science ®Google Scholar
• Ilan Y., Ohana M., Pappo O., Margalit M., Lalazar G., Engelhardt D., Rabbani E., Nagler A. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T-lymphocyte plasticity. Transplantation 2007; 83: 458–467
   PubMedGoogle Scholar
• Ishihara S., Nieda M., Kitayama J., Osada T., Yabe T., Ishikawa Y., Nagawa H., Muto T., Juji T. CD8(+)NKR-P1A(+) T-cells preferentially accumulate in human liver. Eur. J. Immunol. 1999; 29: 2406–2413
   PubMedGoogle Scholar
• Iwamura C., Nakayama T. Role of α -galactosylceramide-activated Vα 14 natural killer T-cells in the regulation of allergic diseases. Allergol. Int. 2007; 56: 1–6
   PubMedGoogle Scholar
• Jahng A. W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., Koezuka Y., Kumar V. Activation of natural killer T-cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 2001; 194: 1789–1799
   PubMed Web of Science ®Google Scholar
• Jinquan T., Li W., Yuling H., Lang C. All roads lead to Rome: Pathways of NKT cells promoting asthma. Arch. Immunol. Ther. Exp. (Warsz.) 2006; 54: 335–340
   PubMedGoogle Scholar
• Kakimi K., Guidotti L. G., Koezuka Y., Chisari F. V. Natural killer T-cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 2000; 192: 921–930
   PubMed Web of Science ®Google Scholar
• Kawakami K., Kinjo Y., Yara S., Koguchi Y., Uezu K., Nakayama T., Taniguchi M., Saito A. Activation of Vα 14(+) natural killer T-cells by α-galactosylceramide results in development of TH1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 2001a; 69: 213–220
   PubMed Web of Science ®Google Scholar
• Kawakami K., Kinjo Y., Yara S., Uezu K., Koguchi Y., Tohyama M., Azuma M., Takeda K., Akira S., Saito A. Enhanced γ -interferon production through activation of Vα 14(+) natural killer T-cells by α -galactosylceramide in IL-18-deficient mice with systemic cryptococcosis. Infect. Immun. 2001b; 69: 6643–6650
   PubMedGoogle Scholar
• Kawakami K., Tohyama M., Qifeng X., Saito A. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: Effects of IL-12. Infect. Immun. 1997; 65: 1307–1312
   PubMed Web of Science ®Google Scholar
• Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of Vα 14 NKT cells by glycosylceramides. Science 1997; 278: 1626–1629
   PubMed Web of Science ®Google Scholar
• Kinjo Y., Kronenberg M. Vα 14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J. Clin. Immunol. 2005; 25: 522–533
   PubMed Web of Science ®Google Scholar
• Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano T., Taniguchi M., Nishimura T. The natural killer T (NKT)-cell ligand α -galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 1999; 189: 1121–1128
   PubMed Web of Science ®Google Scholar
• Kronenberg M., Engel I. On the road: Progress in finding the unique pathway of invariant NKT cell differentiation. Curr. Opin. Immunol 2007; 19: 186–193
   PubMedGoogle Scholar
• Lalazar G., Preston S., Lador A., Pappo O., Zolotarov L., Ilan Y. Alleviation of ConA immune mediated hepatitis via glycolipids: The role of β vs. α configuration in determining NKT lymphocyte distribution and the TH1/TH2 paradigm. J. Hepatology 2006a; 44: S237
   Google Scholar
• Lalazar G., Preston S., Zigmond E., Ben Yaacov A., Ilan Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 2006b; 6: 1249–1253
   PubMed Web of Science ®Google Scholar
• Laloux V., Beaudoin L., Ronet C., Lehuen A. Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes. J. Immunol. 2002; 168: 3251–3258
   PubMedGoogle Scholar
• Liu Y., Bittman R. Synthesis of fluorescent lactosylceramide stereoisomers. Chem. Phys. Lipids 2006; 142: 58–69
   PubMedGoogle Scholar
• Lu X., Song L., Metelitsa L. S., Bittman R. Synthesis and evaluation of an α -C-galactosylceramide analogue that induces TH1-biased responses in human natural killer T-cells. Chembiochem 2006; 7: 1750–1756
   PubMedGoogle Scholar
• Margalit M., Ghazala S. A., Alper R., Elinav E., Klein A., Doviner V., Sherman Y., Thalenfeld B., Engelhardt D., Rabbani E., Ilan Y. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 289: G917–925
   PubMedGoogle Scholar
• Matsuda J. L., Naidenko O. V., Gapin L., Nakayama T., Taniguchi M., Wang C. R., Koezuka Y., Kronenberg M. Tracking the response of natural killer T-cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 2000; 192: 741–754
   PubMed Web of Science ®Google Scholar
• Mattner J., Debord K. L., Ismail N., Goff R. D., Cantu C., 3rd, Zhou D., Saint-Mezard P., Wang V., Gao Y., Yin N., Hoebe K., Schneewind O., Walker D., Beutler B., Teyton L., Savage P. B., Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525–529
   PubMed Web of Science ®Google Scholar
• Menachem Y., Trop S., Kolker O., Shibolet O., Alper R., Nagler A., Ilan Y. Adoptive transfer of NK 1.1+ lymphocytes in immune-mediated colitis: A pro-inflammatory or a tolerizing subgroup of cells?. Microbes Infect. 2005; 7: 825–835
   PubMedGoogle Scholar
• Meyer E. H., DeKruyff R. H., Umetsu D. T. iNKT cells in allergic disease. Curr. Top. Microbiol. Immunol. 2007; 314: 269–291
   PubMed Web of Science ®Google Scholar
• Miyake S., Yamamura T. NKT cells and autoimmune diseases: Unraveling the complexity. Curr. Top. Microbiol. Immunol. 2007; 314: 251–267
   PubMedGoogle Scholar
• Miyake S., Yamamura T. Therapeutic potential of glycolipid ligands for natural killer (NK) T-cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005; 5: 315–322
   PubMedGoogle Scholar
• Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T-cells. Nature 2001; 413: 531–534
   PubMed Web of Science ®Google Scholar
• Morel P. A., Feili-Hariri M., Coates P. T., Thomson A. W. Dendritic cells, T-cell tolerance and therapy of adverse immune reactions. Clin. Exp. Immunol. 2003; 133: 1–10
   PubMed Web of Science ®Google Scholar
• Motsinger A., Azimzadeh A., Stanic A. K., Johnson R. P., Van Kaer L., Joyce S., Unutmaz D. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T-cells. J. Virol. 2003; 77: 8153–8158
   PubMedGoogle Scholar
• Nishimura T., Kitamura H., Iwakabe K., Yahata T., Ohta A., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano T., Taniguchi M., Nakui M., Sekimoto M., Koda T. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T-lymphocytes. Int. Immunol. 2000; 12: 987–994
   PubMed Web of Science ®Google Scholar
• Novak J., Griseri T., Beaudoin L., Lehuen A. Regulation of type 1 diabetes by NKT cells. Int. Rev. Immunol. 2007; 26: 49–72
   PubMed Web of Science ®Google Scholar
• Ohteki T., MacDonald H. R. Major histocompatibility complex class I related molecules control the development of CD4+CD8− and CD4−CD8− subsets of natural killer 1.1+ T-cell receptor-α/β+ cells in the liver of mice. J. Exp. Med. 1994; 180: 699–704
   PubMed Web of Science ®Google Scholar
• Ortaldo J. R., Young H. A., Winkler-Pickett R. T., Bere E. W., Jr, Murphy W. J., Wiltrout R. H. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 2004; 172: 943–953
   PubMed Web of Science ®Google Scholar
• Osman Y., Kawamura T., Naito T., Takeda K., Van Kaer L., Okumura K., Abo T. Activation of hepatic NKT cells and subsequent liver injury following administration of α -galactosylceramide. Eur. J. Immunol. 2000; 30: 1919–1928
   PubMed Web of Science ®Google Scholar
• Parekh V. V., Singh A. K., Wilson M. T., Olivares-Villagomez D., Bezbradica J. S., Inazawa H., Ehara H., Sakai T., Serizawa I., Wu L., Wang C. R., Joyce S., Van Kaer L. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α - and β -anomeric glycolipids. J. Immunol. 2004; 173: 3693–3706
   PubMed Web of Science ®Google Scholar
• Park Y. K., Lee J. W., Ko Y. G., Hong S., Park S. H. Lipid rafts are required for efficient signal transduction by CD1d. Biochem. Biophys. Res. Commun. 2005; 327: 1143–1154
   PubMed Web of Science ®Google Scholar
• Porcelli S., Yockey C. E., Brenner M. B., Balk S. P. Analysis of T-cell antigen receptor (TCR) expression by human peripheral blood CD4−CD8−α /β T-cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain. J. Exp. Med., 178: 1–16
   PubMedGoogle Scholar
• Porubsky S., Speak A. O., Luckow B., Cerundolo V., Platt F. M., Grone H. J. Normal development and function of invariant natural killer T-cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. USA 2007; 104: 5977–5982
   PubMed Web of Science ®Google Scholar
• Prohaska S. S., Scherer D. C., Weissman I. L., Kondo M. Developmental plasticity of lymphoid progenitors. Sem. Immunol. 2002; 14: 377–384
   PubMed Web of Science ®Google Scholar
• Roark J. H., Park S. H., Jayawardena J., Kavita U., Shannon M., Bendelac A. CD1.1 expression by mouse antigen-presenting cells and marginal zone B-cells. J. Immunol. 1998; 160: 3121–3127
   PubMed Web of Science ®Google Scholar
• Rothenberg E. V., Dionne C. J. Lineage plasticity and commitment in T-cell development. Immunol. Rev. 2002; 187: 96–115
   PubMed Web of Science ®Google Scholar
• Rothenberg E. V. Negotiation of the T-lineage fate decision by transcription-factor interplay and microenvironmental signals. Immunity 2007; 26: 690–702
   PubMed Web of Science ®Google Scholar
• Safadi R., Zigmond E., Pappo O., Shalev Z., Ilan Y. Amelioration of hepatic fibrosis via β -glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int. Immunol. 2007; 19: 1021–1029
   PubMed Web of Science ®Google Scholar
• Schmieg J., Yang G., Franck R. W., Van Rooijen N., Tsuji M. Glycolipid presentation to natural killer T-cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA 2005; 102: 1127–1132
   PubMed Web of Science ®Google Scholar
• Sehgal P. B. Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochim. Pol. 2003; 50: 583–594
   PubMed Web of Science ®Google Scholar
• Shibolet O., Alper R., Zlotogarov L., Thalenfeld B., Engelhardt D., Rabbani E., Ilan Y. Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. Oncology 2004a; 66: 323–330
   PubMedGoogle Scholar
• Shibolet O., Kalish Y., Klein A., Alper R., Zolotarov L., Thalenfeld B., Engelhardt D., Rabbani E., Ilan Y. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. J. Leukocyte Biol. 2004b; 75: 76–86
   PubMedGoogle Scholar
• Singh N., Hong S., Scherer D. C., Serizawa I., Burdin N., Kronenberg M., Koezuka Y., Van Kaer L. Cutting edge: Activation of NK T-cells by CD1d and α -galactosylceramide directs conventional T-cells to the acquisition of a TH2 phenotype. J. Immunol. 1999; 163: 2373–2377
   PubMed Web of Science ®Google Scholar
• Singh R. D., Puri V., Valiyaveettil J. T., Marks D. L., Bittman R., Pagano R. E. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol. Biol. Cell 2003; 14: 3254–3265
   PubMedGoogle Scholar
• Skold M., Behar S. M. Role of CD1d-restricted NKT cells in microbial immunity. Infect. Immun. 2003; 71: 5447–5455
   PubMedGoogle Scholar
• Smyth M. J., Thia K. Y., Street S. E., Cretney E., Trapani J. A., Taniguchi M., Kawano T., Pelikan S. B., Crowe N. Y., Godfrey D. I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000; 191: 661–668
   PubMed Web of Science ®Google Scholar
• Sonnino S., Mauri L., Chigorno V., Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology 2007; 17: 1R–13R
   PubMed Web of Science ®Google Scholar
• Sriram V., Cho S., Li P., O'Donnell P. W., Dunn C., Hayakawa K., Blum J. S., Brutkiewicz R. R. Inhibition of glycolipid shedding rescues recognition of a CD1+ T-cell lymphoma by natural killer T (NKT)-cells. Proc. Natl. Acad. Sci. USA 2002; 99: 8197–8202, 2002
   PubMed Web of Science ®Google Scholar
• Stanic A. K., De Silva A. D., Park J. J., Sriram V., Ichikawa S., Hirabyashi Y., Hayakawa K., Van Kaer L., Brutkiewicz R. R., Joyce S. Defective presentation of the CD1d1-restricted natural Vα 14Jα 18 NKT lymphocyte antigen caused by β -D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 2003a; 100: 1849–1854
   PubMedGoogle Scholar
• Stanic A. K., Park J. J., Joyce S. Innate self-recognition by an invariant, rearranged T-cell receptor and its immune consequences. Immunology 2003b; 109: 171–184
   PubMedGoogle Scholar
• Stenger S., Hanson D. A., Teitelbaum R., Dewan P., Niazi K. R., Froelich C. J., Ganz T., Thoma-Uszynski S., Melian A., Bogdan C., Porcelli S. A., Bloom B. R., Krensky A. M., Modlin R. L. An antimicrobial activity of cytolytic T-cells mediated by granulysin. Science 1998; 282: 121–125
   PubMed Web of Science ®Google Scholar
• Stockinger B., Bourgeois C., Kassiotis G. CD4+ memory T-cells: Functional differentiation and homeostasis. Immunol. Rev. 2006; 211: 39–48
   PubMed Web of Science ®Google Scholar
• Taniguchi M., Harada M., Kojo S., Nakayama T., Wakao H. The regulatory role of Vα 14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 2003; 21: 483–513
   PubMed Web of Science ®Google Scholar
• Taniguchi M., Nakayama T. Recognition and function of Vα 14 NKT cells. Sem. Immunol. 2000; 12: 543–550
   PubMed Web of Science ®Google Scholar
• Terabe M., Berzofsky J. A. Immunoregulatory T-cells in tumor immunity. Curr. Opin. Immunol. 2004; 16: 157–162
   PubMed Web of Science ®Google Scholar
• Trop S., Nagler A., Ilan Y. Role of NK1.1+ and AsGm-1+ cells in oral immunoregulation of experimental colitis. Inflamm. Bowel Dis. 2003; 9: 75–86
   PubMedGoogle Scholar
• Trop S., Samsonov D., Gotsman I., Alper R., Diment J., Ilan Y. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 1999; 29: 746–755
   PubMed Web of Science ®Google Scholar
• Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 2006; 63: 1889–1898
   PubMedGoogle Scholar
• Tupin E., Kinjo Y., Kronenberg M. The unique role of natural killer T-cells in the response to microorganisms. Nat. Rev. Microbiol. 2007; 5: 405–417
   PubMed Web of Science ®Google Scholar
• Ulrichs T., Porcelli S. A. CD1 proteins: Targets of T-cell recognition in innate and adaptive immunity. Rev. Immunogenet. 2000; 2: 416–432
   PubMedGoogle Scholar
• Van Kaer L. Natural killer T-cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 2004a; 82: 315–322
   PubMed Web of Science ®Google Scholar
• Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T-cells. Immunol. Res. 2004b; 30: 139–153
   PubMed Web of Science ®Google Scholar
• Van Kaer L. α -Galactosylceramide therapy for autoimmune diseases: Prospects and obstacles. Nat. Rev. Immunol. 2005; 5: 31–42
   PubMed Web of Science ®Google Scholar
• Van Kaer L. NKT cells: T-lymphocytes with innate effector functions. Curr. Opin. Immunol. 2007; 19: 354–364
   PubMed Web of Science ®Google Scholar
• Weaver C. T., Harrington L. E., Mangan P. R., Gavrieli M., Murphy K. M. TH17: An effector CD4 T-cell lineage with regulatory T-cell ties. Immunity 2006; 24: 677–688
   PubMed Web of Science ®Google Scholar
• Wilson M. T., Singh A. K., Van Kaer L. Immunotherapy with ligands of natural killer T-cells. Trends Mol. Med. 2002; 8: 225–231
   PubMed Web of Science ®Google Scholar
• Wilson M. T., Van Kaer L. Natural killer T-cells as targets for therapeutic intervention in autoimmune diseases. Curr. Pharm. Des. 2003; 9: 201–220
   PubMed Web of Science ®Google Scholar
• Yamamura T., Miyamoto K., Illes Z., Pal E., Araki M., Miyake S. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr. Top. Med. Chem. 2004; 4: 561–567
   PubMedGoogle Scholar
• Yu K. O., Im J. S., Molano A., Dutronc Y., Illarionov P. A., Forestier C., Fujiwara N., Arias I., Miyake S., Yamamura T., Chang Y. T., Besra G. S., Porcelli S. A. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α -galactosylceramides. Proc. Natl. Acad. Sci. USA 2005; 102: 3383–3388
   PubMed Web of Science ®Google Scholar
• Zajonc D. M., Cantu C., 3rd, Mattner J., Zhou D., Savage P. B., Bendelac A., Wilson I. A., Teyton L. Structure and function of a potent agonist for the semi-invariant natural killer T-cell receptor. Nat. Immunol. 2005; 6: 810–818
   PubMed Web of Science ®Google Scholar
• Zhou D. The immunological function of iGb3. Curr. Protein Pept. Sci. 2006; 7: 325–333
   PubMedGoogle Scholar
• Zhou D., Mattner J., Cantu C., 3rd, Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y. P., Yamashita T., Teneberg S., Wang D., Proia R. L., Levery S. B., Savage P. B., Teyton L., Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004; 306: 1786–1789
   PubMed Web of Science ®Google Scholar
• Zigmond E., Preston S., Pappo O., Lalazar G., Margalit M., Shalev Z., Zolotarov L., Friedman D., Alper R., Ilan Y. β -Glucosylceramide: A novel method for enhancement of natural killer T-lymphocyte plasticity in murine models of immune-mediated disorders. Gut 2007; 56: 82–89, 2007
   PubMed Web of Science ®Google Scholar
• Zlotnik A., Godfrey D. I., Fischer M., Suda T. Cytokine production by mature and immature CD4−CD8− T-cells. α β -T-cell receptor+ CD4−CD8− T-cells produce IL-4. J. Immunol. 1992; 149: 1211–1215
   PubMedGoogle Scholar